Medical Innovation Exchange

ASCO: I-Mab, Junshi's cancer combo performs best as a first-line NSCLC treatment, with signals for CD73 as a biomarker


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.